Syngene International Limited (SYNGENE.NS)
INR 627.95
(-0.96%)
INR 627.95
(-0.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.99 Billion INR | -65.21% |
| 2022 | 17.23 Billion INR | 30.2% |
| 2021 | 13.23 Billion INR | 12.63% |
| 2020 | 11.74 Billion INR | 20.38% |
| 2019 | 9.76 Billion INR | 20.67% |
| 2018 | 8.08 Billion INR | 20.02% |
| 2017 | 6.73 Billion INR | 16.85% |
| 2016 | 5.76 Billion INR | 21.45% |
| 2015 | 4.74 Billion INR | 22.39% |
| 2014 | 3.88 Billion INR | 28.9% |
| 2013 | 3.01 Billion INR | 22.41% |
| 2012 | 2.45 Billion INR | 21.13% |
| 2011 | 2.03 Billion INR | 16.07% |
| 2010 | 1.74 Billion INR | 14.99% |
| 2009 | 1.52 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.53 Billion INR | -4.43% |
| 2024 Q2 | 5.24 Billion INR | 6.01% |
| 2023 Q4 | 1.6 Billion INR | -66.63% |
| 2023 Q3 | 4.8 Billion INR | 1.01% |
| 2023 FY | 5.99 Billion INR | -65.21% |
| 2023 Q1 | 4.6 Billion INR | -3.75% |
| 2023 Q2 | 4.75 Billion INR | 3.37% |
| 2022 FY | 17.23 Billion INR | 30.2% |
| 2022 Q2 | 4.24 Billion INR | 7.88% |
| 2022 Q3 | 4.27 Billion INR | 0.83% |
| 2022 Q1 | 3.93 Billion INR | 19.48% |
| 2022 Q4 | 4.77 Billion INR | 11.74% |
| 2021 Q3 | 3.46 Billion INR | -1.51% |
| 2021 Q4 | 3.29 Billion INR | -5.05% |
| 2021 FY | 13.23 Billion INR | 12.63% |
| 2021 Q1 | 3.25 Billion INR | 28.1% |
| 2021 Q2 | 3.51 Billion INR | 8.28% |
| 2020 Q4 | 2.53 Billion INR | -25.21% |
| 2020 Q1 | 2.43 Billion INR | 29.14% |
| 2020 FY | 11.74 Billion INR | 20.38% |
| 2020 Q2 | 3.11 Billion INR | 28.15% |
| 2020 Q3 | 3.39 Billion INR | 8.79% |
| 2019 Q1 | 2.43 Billion INR | 62.74% |
| 2019 Q2 | 2.56 Billion INR | 5.26% |
| 2019 Q4 | 1.88 Billion INR | -34.63% |
| 2019 Q3 | 2.88 Billion INR | 12.53% |
| 2019 FY | 9.76 Billion INR | 20.67% |
| 2018 Q3 | 2.27 Billion INR | 14.57% |
| 2018 Q2 | 1.98 Billion INR | -8.02% |
| 2018 Q1 | 2.15 Billion INR | -1.78% |
| 2018 Q4 | 1.49 Billion INR | -34.2% |
| 2018 FY | 8.08 Billion INR | 20.02% |
| 2017 Q2 | 1.72 Billion INR | 9.07% |
| 2017 Q4 | 2.19 Billion INR | 15.71% |
| 2017 Q1 | 1.57 Billion INR | 11.69% |
| 2017 FY | 6.73 Billion INR | 16.85% |
| 2017 Q3 | 1.89 Billion INR | 10.29% |
| 2016 Q1 | 1.35 Billion INR | -9.72% |
| 2016 Q4 | 1.41 Billion INR | -5.04% |
| 2016 Q3 | 1.48 Billion INR | 7.44% |
| 2016 Q2 | 1.38 Billion INR | 2.06% |
| 2016 FY | 5.76 Billion INR | 21.45% |
| 2015 Q1 | 1.06 Billion INR | -3.27% |
| 2015 FY | 4.74 Billion INR | 22.39% |
| 2015 Q4 | 1.5 Billion INR | 20.16% |
| 2015 Q3 | 1.25 Billion INR | 3.78% |
| 2015 Q2 | 1.2 Billion INR | 12.99% |
| 2014 FY | 3.88 Billion INR | 28.9% |
| 2014 Q4 | 1.1 Billion INR | 13.14% |
| 2014 Q1 | 893.8 Million INR | 0.0% |
| 2014 Q2 | 968.2 Million INR | 8.32% |
| 2014 Q3 | 974 Million INR | 0.6% |
| 2013 FY | 3.01 Billion INR | 22.41% |
| 2012 FY | 2.45 Billion INR | 21.13% |
| 2011 FY | 2.03 Billion INR | 16.07% |
| 2010 FY | 1.74 Billion INR | 14.99% |
| 2009 FY | 1.52 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 85.343% |
| Blue Jet Healthcare Limited | 531.85 Million INR | -1027.198% |
| Concord Biotech Limited | 1.45 Billion INR | -310.7% |
| Dishman Carbogen Amcis Limited | 5.14 Billion INR | -16.467% |
| Jubilant Ingrevia Limited | 6.67 Billion INR | 10.12% |
| Lyka Labs Limited | 599.4 Million INR | -900.155% |
| Panacea Biotec Limited | 1.99 Billion INR | -200.441% |
| Piramal Pharma Limited | 19.91 Billion INR | 69.896% |
| SMS Lifesciences India Limited | 602.96 Million INR | -894.25% |
| Supriya Lifescience Limited | 1.08 Billion INR | -455.016% |
| TAKE Solutions Limited | 396.91 Million INR | -1410.418% |
| Zota Health Care Limited | 457.83 Million INR | -1209.424% |